SCHEMBL6317610

SCHEMBL6317610

COc1cccc(C(=O)Nc2onc(-c3cccs3)c2C(N)=O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.59
NPC1 O15118 6/20 0.59
RAB9A P51151 6/20 0.59
LMNA P02545 2/20 0.59
SMN1; SMN2 Q16637 6/20 0.58
ALDH1A1 P00352 5/20 0.58
HPGD P15428 3/20 0.58
NPSR1 Q6W5P4 2/20 0.58
FLT3 P36888 1/20 0.50
MAPT P10636 2/20 0.47
TDP1 Q9NUW8 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
TP53 P04637 1/20 0.47
POLB P06746 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
USP2 O75604 1/20 0.46
OPRK1 P41145 1/20 0.46
ADCY1 Q08828 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315171 0.89 ADCY1 (0.56) KDM4ENPC1RAB9ALMNASMN1; SMN2
SCHEMBL6316198 0.85 FLT3 (0.48) KDM4ENPC1RAB9ALMNASMN1; SMN2
SCHEMBL6317501 0.84 MAPT (0.53) KDM4ENPC1RAB9ALMNASMN1; SMN2
SCHEMBL6316679 0.84 SMN1; SMN2 (0.55) KDM4ENPC1RAB9ALMNASMN1; SMN2
SCHEMBL6315892 0.84 MAPT (0.50) KDM4ENPC1RAB9ALMNASMN1; SMN2
SCHEMBL6315689 0.84 FLT3 (0.48) KDM4ENPC1RAB9ALMNASMN1; SMN2
SCHEMBL6315760 0.84 KMT2A (0.54) KDM4ENPC1RAB9ALMNASMN1; SMN2
SCHEMBL6315115 0.84 MAPT (0.57) KDM4ERAB9ALMNASMN1; SMN2ALDH1A1
SCHEMBL6314638 0.84 ALDH1A1 (0.54) KDM4ENPC1RAB9ALMNASMN1; SMN2
SCHEMBL6317129 0.83 MAPK8 (0.57) RAB9ASMN1; SMN2ALDH1A1HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050228018-A1 Chemical compounds AVENTIS PHARMACEUTICALS INC. (US) 2005-10-13 US disclosed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 KDM4E 1382/4885NPC1 3741/4885RAB9A 1754/4885
US-20050228018-A1 Chemical compounds CMA1, TPSB2, TPSG1 KDM4E 3000/4885NPC1 806/4885RAB9A 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.